Peptech patent approved
Tuesday, 15 July, 2003
Peptech's application for a patent on antibodies or antibody fragments that bind to a specific tumour necrosis factor (TNF) has been given the green light by US patent authorities.
Managing director Mr Stephen Kwik noted that the new patent enhanced the company's already considerable anti-TNF patent portfolio, and offered the potential for further coverage under the current description.
"As the peptide represents a portion of the TNF molecule, anti-TNF antibodies that bind the peptide could fall under the scope of the patent," Kwik said.
Peptech has already licensed its technology in the fields of antibody therapeutics for inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
